Indefinite Delivery Contract SPE2DU25D9262

The Defense Logistics Agency (DLA) Troop Support Medical Supply Chain is planning to issue a solicitation for the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) contracts. The purpose is to establish Prime Vendor Contracts to provide worldwide pharmaceutical support, including brand, generic, and specialty drugs, as well as related medical products, to the Defense Health Agency (DHA), Department of Defense (DoD) customers, the United States Coast Guard, Designated Providers, Other Government Agencies, and the US Naval Fleet. The intended contract vehicles are firm-fixed price, requirements-type contracts with a 30-month base period and three 30-month option periods, with an estimated total value of $30.3 billion. The DLA plans to make multiple regional awards, with at least three different contractors to be selected across the North/EUCOM, West/PACOM, South/SOUTHCOM, and Fleet line items. Both primary and backup suppliers will provide separate distribution fees for brand/generic and specialty pharmaceuticals to support normal and contingency operations globally. This is an unrestricted, fully competitive acquisition using a Lowest Price Technically Acceptable (LPTA) evaluation criteria, with the potential for a reverse auction to determine the final distribution fees.

The current federal contract IDV award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. This IDC enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical supply needs of military health facilities worldwide.